Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: life extension

To answer this question, an internal team of scientists, consisting of researchers affiliated with the Buck Institute for Research on Ageing, and researchers from Nanjing University decided to modify both the Insulin and the rapamycin pathways of a group of C.elegans worms, expecting to see a cumulative result of a 130% increase in lifespan. However, instead of seeing a cumulative effect in lifespan, the worms lived five times longer than they normally would.

“The synergistic extension is really wild. The effect isn’t one plus one equals two, it’s one plus one equals five. Our findings demonstrate that nothing in nature exists in a vacuum; in order to develop the most effective anti-aging treatments we have to look at longevity networks rather than individual pathways.” – Jarad Rollins of Nanjing University.

What could this mean for human regenerative medicine? Humans are not worms, however on a cellular level they do possess very similar biology. Both the insulin pathway and the rapamycin pathway are what is known as ‘conserved’ between humans and C.elegans, meaning that these pathways have been maintained in both organisms. In the distant past, both humans and C.elegans had a common ancestor, in exactly the same way as humans and Chimpanzees have a common ancestor. Evolution has changed our bodies significantly over the millions of years that humans and C.elegans have diverged from one another, but a lot of our fundamental biological functions remain largely unchanged.

Read more | >

**Low birth weight tied to accelerated aging in boys**

A study in Pediatrics found that boys who weigh less than 2 pounds at birth aged faster and were five years older biologically in their early 30s, compared with boys who were born at the same time but whose birth weights were normal. The findings were based on the genes of 45 individuals who were extremely low birth weight and those of 47 whose birth weights were normal.

MONDAY, May 17, 2021 (HealthDay News) — Boys who weigh less than 2 pounds at birth don’t age as well as their normal-weight peers, a long-term study finds.

Canadian researchers have followed a group of extremely low birth weight (ELBW) babies and their normal-weight counterparts since 1977.

When participants were in their early 30s, researchers compared the genes of 45 who were ELBW babies with those of 47 whose birth weight was normal.

Read more | >

The secret to longevity is already in the animals around us.

Some species live unexpectedly long lives. By studying how they do it, researchers hope to pinpoint factors affecting human longevity.

By Bob Holmes.

Life, for most of us, ends far too soon — hence the effort by biomedical researchers to find ways to delay the aging process and extend our stay on Earth. But there’s a paradox at the heart of the science of aging: The vast majority of research focuses on fruit flies, nematode worms and laboratory mice, because they’re easy to work with and lots of genetic tools are available. And yet, a major reason that geneticists chose these species in the first place is because they have short lifespans. In effect, we’ve been learning about longevity from organisms that are the least successful at the game.

Read more | >

Most important part comes at 1:49 where Liza talks about gene therapies for people to stop people from aging, reaching homeostasis, or even exceeding it a little bit.

In this video Liz introduces BioViva Science and how the company works with its partners in delivering gene therapies.

Liz Parrish is the Founder and CEO of BioViva Sciences USA Inc. BioViva is committed to extending healthy lifespans using gene therapy. Liz is known as “the woman who wants to genetically engineer you,” she is a humanitarian, entrepreneur, author and innovator and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of gene therapy, she serves as a motivational speaker to the public at large for BioViva and the life sciences. She is actively involved in international educational media outreach and is a founding member of the International Longevity Alliance (ILA). She is the founder of the BioTrove Podcasts, found at iTunes, which is committed to offering a meaningful way for people to learn about current technologies. She is also a founding member of the American Longevity Alliance (ALA) a 501©(3) nonprofit trade association that brings together individuals, companies, and organizations who work in advancing the emerging field of cellular & regenerative medicine with the aim to get governments to consider aging a disease.

BioViva https://bioviva-science.com.
***********************************************************************************
If you would like to support our channel, we’d love a coffee…thank you! https://www.buymeacoffee.com/mhealthspan.

Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. It is the responsibility of you and your healthcare providers to make all decisions regarding your health. Products or services mentioned in this video are not a recommendation or medical advice.

Audio Copyright Disclaimer:
Please note that we have full authorization to the music that we used in our videos as they were created using the service WeVideo which provides the rights to the music. The rights are detailed in the terms of use that can be reviewed here https://www.wevideo.com/terms-of-use and any following inquiries should be addressed to [email protected].

Disclaimer: The opinions and advice expressed in this video are those of the speakers and do not represent the views and opinions of the organizer.

#LizParrish #Aging #GeneTherapy

Read more | >

In our ongoing search to continuously improve our health, we occasionally pay lip service to the bacteria that live inside our gut. Normally this concern rarely manifests as anything more than occasionally remembering to buy some of those small bottles of pro-biotic yoghurts while shopping for your…

Recent discoveries have led to the conclusion that the gut plays an important role in cognitive function, with a large amount of research into understanding what is known as the gut-brain axis, which is the collective name given to the biochemical signalling pathways which take place between the gastrointestinal tract and the central nervous system. With an ever-increasing understanding of this pathway, along with an expanded understand of the gut flora (which was found to decline with age), researchers started to ask how the gut flora are involved in the ageing process.

In order to test how exactly ageing gut flora effects the gut-brain axis, researchers at the University of East Anglia conducted a faecal transplant from elderly mice into younger mice. Following this transplant, the young mice were then put through a serious of tests to assess their cognitive abilities. The younger mice showed significant changes in their microbial profiles, as well as significantly impaired capacity for spatial learning, as well as a decreased capacity for memorisation. These mice also showed an altered expression of proteins associated with neurotransmission and neuroplasticity, along with changes in the mice’s hippocampus, which is responsible for allowing the mice to memories new information, as well as recalling previous memories.

This research has successfully proven a link between the changing microbiome of the gut and protein expression within the central nervous system. This discovery is exceptionally good news, as not only is the problem potentially fairly easy to fix (with an aforementioned faecal transplant), but it also provides clues as to how we might compensate for this age related change in the gut microbiome with medication tailors to mimic the role of a young microbiome. Either way, the discovery has opened the door to a number of exciting prospects for regenerative medicine, along with maybe highlighting the fact that we should really start considering our gut bacteria as more than just a collection of microorganisms, and more of a collection of symbiotic organisms that benefit us in ways that we are only just beginning to understand.

Read more | >

To begin with, why do we use mice in medical and biological research? The answer to this question is fairly straight forward. Mice are cheap, they grow quickly, and the public rarely object to experimentations involving mice. However, mice offer something that is far more important than simple pragmatism, as despite being significantly smaller and externally dissimilar to humans, our two species share an awful lot of similarities. Almost every gene found within mice share functions with genes found within humans, with many genes being essentially identical (with the obvious exception of genetic variation found within all species). This means that anatomically mice are remarkably similar to humans.

Now, this is where for the sake of clarity it would be best to break down biomedical research into two categories. Physiological research and pharmaceutical research, as the success of the mouse model should probably be judges separately depending upon the research that is being carried out. Separating the question of the usefulness of the mouse model down into these two categories also solves the function of more accurately focusing the ire of its critics.

The usefulness of the mouse model in the field of physiological research is largely unquestioned at this point. We have quite literally filled entire textbooks with the information we have gained from studying mice, especially in the field of genetics and pathology. The similarities between humans and mice are so prevalent that it is in fact possible to create functioning human/mouse hybrids, known as ‘genetically engineered mouse models’ or ‘GEMMs’. Essentially, GEMMs are mice that have had the mouse version of a particular gene replaced with its human equivalent. This is an exceptionally powerful tool for medical research, and has led to numerous medical breakthroughs, including most notably our current treatment of acute promyelocytic leukaemia (APL), which was created using GEMMs.

Read more | >

Aging, DNA Repair, And Clinical Innovation — Dr. Morten Scheibye-Knudsen — University of Copenhagen.

Dr. Morten Scheibye-Knudsen is an Associate Professor at the Department of Cellular and Molecular Medicine, and at the Center for Healthy Aging (CEHA), at the University of Copenhagen.

Dr. Scheibye-Knudsen did his MD at the University of Copenhagen and worked briefly as a physician in Denmark and Greenland before turning to science. He did his post-doctoral fellowship at Vilhelm Bohr’s lab at the National Institute on Aging, National Institutes of Health, USA, where he utilized state-of-the art approaches to understand how DNA damage contributes to aging, discovering that neurodegeneration in several premature aging diseases is partly caused by hyperactivation of a DNA damage responsive enzyme called polyADP-ribose polymerase 1 (PARP1). This activation leads to loss of vital metabolites such as Nicotinamide Adenine Dinucleotide (NAD+) and acetyl-CoA. Importantly, this discovery facilitated the realization that we can intervene in the aging process by inhibiting PARP1, augmenting NAD+ levels and increasing acetyl-CoA.

In his own lab Dr. Scheibye-Knudsen continues to focus on understanding aging by combining machine learning based approaches with wet-lab analyses with the goal of developing interventions for age-associated diseases and perhaps aging itself.

Dr. Scheibye-Knudsen is Chief Editor, Frontiers in Aging, and an Advisory Board Member of the Longevity Vision Fund and Molecule Protocol.

Read more | >

Famed longevity pioneer Aubrey de Grey, Chief Science Officer of SENS Research Foundation, joins Geoffrey Woo, Founder and Chairman of Health Via Modern Nutrition Inc., for an enlightening conversation about advances in longevity, the investments and technologies that extend life, and the challenges and opportunities of a world in which people live longer. He walks us through his damage repair therapies with a focus on rejuvenation, prevention, and wearable technologies. Filmed on May 17, 2021. To continue the discussion with fellow Real Vision members on this interview, click here to visit the Exchange: https://rvtv.io/2T7nqZL

Key Learnings: Longevity escape velocity, which is a term de Grey coined, is the idea in which life expectancy is extended longer than the time that is passing, and he estimates a 50% chance that aging could be brought under medical control in as little as 15 years’ time. To learn more about SENS’ research and advancements, please visit their site here: https://www.sens.org/.

Read more | >

Rapamycin has been proven to extend the lifespan of mice, warms and yeast. Lifespan.io is starting a large clinical trial named Participatory Evaluation (of) Aging (with) Rapamycin (for) Longevity Study, or PEARL, to see if the antiaging effects of Rapamycin apply to humans. This will be the first study to see if Rapamycin works as well in humans as it does in mice.

The PEARL trial will follow up to 200 participants over 12 months testing four different Rapamycin dosing regimens. It will be double-blind, randomized, placebo-controlled and registered with clinicaltrials.gov. The principal investigator is Dr. James P Watson at UCLA, who was also a PI for the famous TRIIM trial.

Tests and measurements will be taken, both after 6 and 12 months. These will include autonomic health tests, blood tests, body composition tests, fecal microbiome testing, immune and inflammation health tests, methylation age clock testing and skeletal muscle tests.

Read more | >